Netarsudil — Discount Pricing
Netarsudil is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Netarsudil Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $81.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Netarsudil
Netarsudil is a prescription medication. Ask your doctor if Netarsudil is right for you.
How to Check Netarsudil Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Netarsudil at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Ophthalmology
What Netarsudil is approved for (FDA label)
RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. RHOPRESSA ® is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: January 20, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Netarsudil (FDA label)
Ophthalmic solution containing netarsudil 0.02% (0.2 mg/mL). Ophthalmic solution containing netarsudil 0.02%. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 7d4f0e3a-5b86-4c43-982a-813b22ae7e22. SPL document ID: 82acde68-4935-4dc9-82ff-9ff7f449f893. Label effective date: January 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Netarsudil (FDA label)
The most common adverse reaction is conjunctival hyperemia (53%). Other common adverse reactions, approximately 20% include: corneal verticillata, instillation site pain, and conjunctival hemorrhage. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1‑800-757-9195, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA dosed once daily was conjunctival hyperemia which was reported in 53% of patients.
Source: FDA prescribing information (DailyMed). Set ID: 7d4f0e3a-5b86-4c43-982a-813b22ae7e22. SPL document ID: 82acde68-4935-4dc9-82ff-9ff7f449f893. Label effective date: January 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Netarsudil (FDA label)
None. None. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 7d4f0e3a-5b86-4c43-982a-813b22ae7e22. SPL document ID: 82acde68-4935-4dc9-82ff-9ff7f449f893. Label effective date: January 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.